Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Snapinn

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Therapeutic Innovation & Regulatory Science|September 21, 2018
Responsibilities of Data Monitoring Committees: Consensus RecommendationsBarbara E Bierer, Rebecca Li, Jonathan Seltzer, et al.
JAMA|November 18, 2004
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular eventsPeter M Okin, Richard B Devereux, Sverker Jern, et al.
Lancet (London, England)|April 9, 2002
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLars H Lindholm, Hans Ibsen, Björn Dahlöf, et al.
JAMA|September 24, 2002
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudySverre E Kjeldsen, Björn Dahlöf, Richard B Devereux, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2024
Improving Collection and Analysis of Overall Survival DataLisa R Rodriguez, Nicole J Gormley, Ruixiao Lu, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 24, 2022
Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents-post hoc analyses of the ASCEND-ND and ASCEND-D trialsAjay K Singh, Finnian R McCausland, Brian L Claggett, et al.
Annals of Internal Medicine|August 6, 2003
Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trialRichard B Devereux, Björn Dahlöf, Sverre E Kjeldsen, et al.
Journal of Hypertension|August 27, 2002
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension studyLars H Lindholm, Hans Ibsen, Knut Borch-Johnsen, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Therapeutic Innovation & Regulatory Science|September 21, 2018
Responsibilities of Data Monitoring Committees: Consensus RecommendationsBarbara E Bierer, Rebecca Li, Jonathan Seltzer, et al.
JAMA|November 18, 2004
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular eventsPeter M Okin, Richard B Devereux, Sverker Jern, et al.
Lancet (London, England)|April 9, 2002
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLars H Lindholm, Hans Ibsen, Björn Dahlöf, et al.
JAMA|September 24, 2002
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudySverre E Kjeldsen, Björn Dahlöf, Richard B Devereux, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2024
Improving Collection and Analysis of Overall Survival DataLisa R Rodriguez, Nicole J Gormley, Ruixiao Lu, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 24, 2022
Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents-post hoc analyses of the ASCEND-ND and ASCEND-D trialsAjay K Singh, Finnian R McCausland, Brian L Claggett, et al.
Annals of Internal Medicine|August 6, 2003
Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trialRichard B Devereux, Björn Dahlöf, Sverre E Kjeldsen, et al.
Journal of Hypertension|August 27, 2002
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension studyLars H Lindholm, Hans Ibsen, Knut Borch-Johnsen, et al.
Pageof 4